A Phase II study of ipilimumab plus androgen deprivation therapy in castrate sensitive prostate carcinoma - Stand Up To Cancer

Blog

Posted October 14, 2019

A Phase II study of ipilimumab plus androgen deprivation therapy in castrate sensitive prostate carcinoma

JOIN OUR COMMUNITY

Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Please validate the captcha
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.